logo
Kia reveals a new lineup of electric vans

Kia reveals a new lineup of electric vans

Yahoo27-02-2025

Look for Kia to expand its range of battery electric vans with the launch of the PV5, the opening salvo in a new business strategy as the South Korean automaker aims to increase its production by one million units – all of them EVs.
'We at Kia are unwavering in our belief in electrification,' said Ho-Sung Song, CEO of Kia Motors at 2025 Kia EV Day, a news conference held in Tarragona, Spain near Barcelona earlier this week.
To that end, Kia unveiled a new electric vehicle this week aimed at the light commercial vehicle market.The PV5 is the first in a series of light-duty commercial vans and trucks built on the new modular Electric Global Modular Platform for Service, or E-GMP.S. Derived from Hyundai Motor Group's E-GMP EV architecture, the skateboard platform standardizes batteries, motors, modular body panels, and other components and incorporates them into an architecture that simplifies development and decreases expenditures.
Kia's standard model variants will include Passenger, Cargo, Chassis-Cab, and WAV (Wheelchair-Accessible Vehicle) bodies. The architecture's flexibility will allow Kia to go even further, building Crew, Drop-Side, Box Van, Freezer Box, and Light Camper models. The vehicles will be built at a dedicated plant in South Korea designed to handle small runs of special vehicles through flexible production, although what that might entail wasn't explained further.
Kia will begin building the 184.6-inch-long PV5 for European and Asian markets, including Japan, a first for the Korean automaker. Whether it will come to America remains to be seen.
Light trucks imported into the United States are subject to a 25% tariff enacted by Congress in 1964. There's also existing competition from Detroit automakers and their conservative, brand-loyal customers.
This means that selling most PV5s in America is a no-go. The company could still import the forthcoming Light Camper or the WAV models as PV5s with value-added features and a market price that could help Kia cover the cost of the tariffs without losing money.
Kia CEO Song admitted as much later during an interview. 'This is what we are studying,' Song said. 'But it's not fixed yet.'
Still, even if given the go-ahead, it would be some time before the vehicle would hit our shores.The PV5 will have a 161-horsepower (120 kW) front motor producing 184 pound-feet (250 Nm) of torque from a 51.5-kWh or 71.2-kWh NCM battery, or a 43.3-kWh LFP battery option for the PV5 Cargo.
Kia says that the PV5 powertrain has a 249-mile WLTP range and can be recharged from 10% to 80% in less than 30 minutes using a DC fast charger.
Initially, Kia will offer the three-row PV5 Passenger, which can be optimized for luggage or camping. It was initially developed with Uber for ride-sharing, so it will have a lift-up tailgate and folding seats for passenger/luggage flexibility.
The automaker will also build the PV5 Cargo (High Roof), which has 180 cubic feet (5.1 meters) of space. Standard and long versions will also be available, and like any cargo van, it will be built for two passengers. An L-track mounting system, with sliding tie-down rings that can be positioned in various locations, will be optional.
There will also be a 178-inch-long Chassis Cab featuring the Cargo's finished front end and an unfinished back end that can be developed into various trucks, including a Drop-Side, Box Van, and Freezer Box.
The big game-changer could be the PV5 WAV, though, which was shown in concept form.'What we talk a lot about in the design team is this idea that movement is for everybody. We want everybody to be mobile,' said Jochen Paesen, Kia's Vice-President of Interior Design. 'And then we thought, well, hold on, there's actually huge opportunities; people that don't have mobility, people that maybe we don't think about enough."
Typically, if you need a vehicle adapted for wheelchair or scooter use, you'll buy the vehicle and spend just as much in the aftermarket to have it retrofitted, with a total cost approaching or surpassing six figures. The PV5 WAV allows those with such needs to buy a wheelchair accessible vehicle straight from the factory.
'And coming from the factory, it's thought through,' Paesen said.
Designers placed the entry ramp on the sidewalk side for safety, with a maximum weight capacity of up to 661 pounds. To accommodate wheelchairs or scooters, the second row was moved rearward to make room for mobility devices while equipping its cabin with seatbelts and a harness adapted for wheelchairs. No other automaker in the world offers such a vehicle.
'When you see it standing there, it seems super logical. But it isn't something that many people look at,' Paesen said.
While it feels like the PV5 won't make it to the U.S., it offers a lot of flexibility that would make it an incredible value for a lot of audiences. The WAV is the most likely to be sold here, as it doesn't have any competition and could push other automakers to follow suit. It could even open up a segment of factory-optioned accessibility vehicles if Kia plays its cards right. We've got our fingers crossed.
Love reading Autoblog? Sign up for our weekly newsletter to get exclusive articles, insider insights, and the latest updates delivered right to your inbox. Click here to sign up now!

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The top 10 cars on the market that are the easiest to park in the UK
The top 10 cars on the market that are the easiest to park in the UK

Yahoo

time2 hours ago

  • Yahoo

The top 10 cars on the market that are the easiest to park in the UK

Car models from Ford, Kia, Volkswagen, Fiat and more have been named among the easiest to park with in the UK. While driving is something many motorists enjoy, the act of parking can be a bit more difficult and cause stress for some. It comes as research from Cazoo shows that Gen Z (people born between 1997 and 2012) are the most nervous generation by far when it comes to parking. A survey of more than 2,000 motorists found that 96% within the age group faced 'park-xiety'. Parking can be a cause of stress for some motorists (Image: Getty Images) Additionally, around two-thirds (66%) say they have asked someone else to park their car for them, which is illegal if the person isn't insured on that car. With this in mind, Harry Waring, Motoring Specialist at Cazoo, has shared the 10 best cars currently on the market that are the easiest to park with. A classic first car for a reason, the Fiat 500's compact size, light steering and good all-around visibility make it ideal for slotting into spaces. The Ford Fiesta offers functions such as voice control, rear-view cameras and parking sensors available across a range of its models. Waring adds that it is "responsive and solid on the road and in the car park". All models of the Volkswagen Polo have a range of advanced safety features, such as automatic braking, that could help you avoid a collision when parking. Waring says: "A slightly more premium supermini, the Polo offers an easygoing driving experience with a focus on comfort rather than outright fun." The Mercedes-Benz A-Class is considered to be a good option thanks to being equipped with several parking assistance features. This includes standard reversing cameras, parking sensors, and even active parking assist systems that automatically steer the car into parking spaces. Waring adds: "It's relatively compact hatchback form also helps with manoeuvrability compared to larger vehicles, and second-hand examples are very affordable, despite the premium badge." The Hyundai i10 is an "excellent" car for the city and is a "dream to park" thanks to its small size, light steering and good all-around visibility. Some more expensive models even have rear parking sensors, a rare feature in a car of this size. The Kia Picanto takes the crown for one of the UK's least-expensive and best-value cars, and this approach carries through to parking. Waring adds: "Incredibly practical for urban driving, the Picanto's small size, light controls, and good visibility make it a breeze to park." The Suzuki Ignis has a high driving position, which provides good visibility for the driver, and the light steering helps to make parking straightforward. The Audi A3 is described as a "great practical option" that can be fitted with Park Assist. This helps the driver with both parallel and perpendicular parking. The Skoda Karoq is said to be a "fantastic all-rounder, mid-size SUV" which comes with rear parking sensors as standard. Recommended reading: UK's top 10 stolen car models in the last year revealed (Is yours on the list?) How often should your car's engine oil be changed? Motoring expert reveals all Can you drive any car on comprehensive car insurance? Expert reveals all Higher trims often include front sensors or even a reversing camera. Some models may also offer park assist features that can help to steer into spaces. If you're looking for a seven-seater that's manageable to park, the 5008 is a great option. Higher trims offer a mix of all-around parking sensors, reversing cameras, and park assist.

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Yahoo

time2 hours ago

  • Yahoo

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Business Upturn

time4 hours ago

  • Business Upturn

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) — AriBio Co., Ltd. ('AriBio'), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. Advertisement AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. 'This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide,' said Jai Jun Choung, CEO of AriBio. 'Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions.' 'We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries,' said Isabel Afonso, CEO of Arcera. 'This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs.' The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store